PDL BioPharma (PDLI) Enters into Cooperation Agreement with Engine Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
PDL BioPharma Enters into Cooperation Agreement with Engine Capital
February 28, 2020 8:00 AM ESTINCLINE VILLAGE, Nev., Feb. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with its affiliates, "Engine"), which owns approximately 5.5% of the Company's outstanding shares, pursuant to which Alan L. Bazaar will immediately join PDL's Board of Directors as a Class III director serving until the Company's 2022 Annual Meeting of Stockholders. PDL has also agreed to form a Cost Committee of the Board, chaired by Mr. Bazaar, to oversee cost reduction initiatives... More
